National Bank of Canada FI Boosts Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

National Bank of Canada FI grew its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 161.8% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 116,227 shares of the biopharmaceutical company's stock after acquiring an additional 71,838 shares during the period. National Bank of Canada FI owned 0.11% of Regeneron Pharmaceuticals worth $105,185,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of REGN. Meyer Handelman Co. raised its stake in shares of Regeneron Pharmaceuticals by 11.4% during the third quarter. Meyer Handelman Co. now owns 4,235 shares of the biopharmaceutical company's stock valued at $3,485,000 after acquiring an additional 435 shares during the last quarter. Stifel Financial Corp raised its holdings in shares of Regeneron Pharmaceuticals by 12.2% during the third quarter. Stifel Financial Corp now owns 31,030 shares of the biopharmaceutical company's stock valued at $25,537,000 after purchasing an additional 3,385 shares during the period. LPL Financial LLC boosted its position in shares of Regeneron Pharmaceuticals by 9.3% during the 3rd quarter. LPL Financial LLC now owns 40,733 shares of the biopharmaceutical company's stock worth $33,522,000 after purchasing an additional 3,479 shares in the last quarter. Exchange Traded Concepts LLC grew its stake in shares of Regeneron Pharmaceuticals by 32.7% in the 4th quarter. Exchange Traded Concepts LLC now owns 4,954 shares of the biopharmaceutical company's stock valued at $4,351,000 after buying an additional 1,221 shares during the period. Finally, Monetary Management Group Inc. increased its position in Regeneron Pharmaceuticals by 4.8% in the 3rd quarter. Monetary Management Group Inc. now owns 1,095 shares of the biopharmaceutical company's stock valued at $901,000 after buying an additional 50 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company's stock.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the company's stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $982.05, for a total transaction of $98,205.00. Following the sale, the director now directly owns 18,282 shares of the company's stock, valued at $17,953,838.10. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $982.05, for a total value of $98,205.00. Following the completion of the transaction, the director now directly owns 18,282 shares in the company, valued at approximately $17,953,838.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Bonnie L. Bassler sold 854 shares of the stock in a transaction on Monday, February 26th. The stock was sold at an average price of $979.25, for a total value of $836,279.50. Following the sale, the director now owns 1,382 shares in the company, valued at approximately $1,353,323.50. The disclosure for this sale can be found here. In the last 90 days, insiders sold 10,095 shares of company stock valued at $9,664,476. 8.83% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. Morgan Stanley raised their price objective on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an "overweight" rating in a research note on Wednesday, March 13th. StockNews.com cut shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Tuesday, April 30th. Sanford C. Bernstein began coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, March 12th. They set an "outperform" rating and a $1,125.00 target price for the company. TD Cowen raised their price target on shares of Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the company a "buy" rating in a research report on Wednesday, April 24th. Finally, Barclays boosted their price objective on Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the stock an "overweight" rating in a report on Tuesday, January 23rd. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus target price of $977.77.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock traded up $19.39 during trading hours on Friday, hitting $957.00. 547,373 shares of the company were exchanged, compared to its average volume of 509,442. Regeneron Pharmaceuticals, Inc. has a 52-week low of $684.80 and a 52-week high of $998.33. The company has a current ratio of 6.40, a quick ratio of 4.94 and a debt-to-equity ratio of 0.10. The firm has a fifty day simple moving average of $943.75 and a 200 day simple moving average of $897.24. The stock has a market capitalization of $105.04 billion, a price-to-earnings ratio of 28.27, a P/E/G ratio of 2.74 and a beta of 0.17.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.73 by $1.13. The firm had revenue of $3.43 billion for the quarter, compared to analyst estimates of $3.29 billion. Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. The business's revenue was up .6% on a year-over-year basis. During the same period in the previous year, the company posted $10.96 earnings per share. Research analysts predict that Regeneron Pharmaceuticals, Inc. will post 38.86 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.